Results from the phase 3 LITESPARK-012 trial (NCT04736706) demonstrate that intensifying an established first-line regimen ...
EV-304 trial. The U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental biologics license application for enfortumab vedotin-ejfv (Padcev) in combination with ...
Anjali Albanese spoke about the unique emotional and psychosocial challenges faced by younger adults following a cancer ...
Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its ...
Mirvetuximab soravtansine shows 16.4-month OS in ovarian cancer, though poor ECOG status and toxicity significantly impact ...
Because the immune system resides beneath the skin's barrier, the initial cellular mutation caused by UV light occurs before ...
Dr. Don Dizon discusses why early fertility referral and avoiding clinical assumptions are vital for young breast cancer patients at diagnosis. According to Dizon, the discussion regarding fertility ...
Letrozole monotherapy failed to show noninferiority compared to standard chemotherapy followed by letrozole as a first-line ...
Explore how Jessica MacIntyre, ONS President, is transforming oncology care through APP fellowships, a new skin toxicity ...
Shachar emphasized that the key takeaway is the need for proactive and consistent toxicity monitoring across all patients ...
Agarwal emphasized that safe drug administration and toxicity management require coordinated action across multiple levels of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results